Diagnosis of Lymphohistiocytic Hemophagocytosis in Intensive Care

Sponsor
University Hospital, Strasbourg, France
Study ID
NCT07343037
Status
Recruiting
Apply to this trial

Conditions

  • Cirrhosis, Liver
  • Hepatic Insufficiency

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Study Details

Patients with hepatocellular insufficiency and/or cirrhosis are at risk of developing invasive fungal infections, particularly in critical care settings. In international recommendations, voriconazole is positioned as the first-line treatment for invasive aspergillosis. However, this molecule-and the azole class of antifungals-is associated with frequent hepatic toxicity. Available since 2018, isavuconazole appears to be better tolerated in patients without pre-existing liver dysfunction. The aim of this study is to retrospectively evaluate the validity of the hscore in intensive care and resuscitation patients.

Key Dates

First listed
Jan 15, 2026
Start date
Aug 29, 2025
Status verified
Jan 2026
Primary completion
Aug 31, 2026
Completion
Aug 29, 2026

Study Design

Enrollment
100 participants (estimated)

Primary Outcome Measure

hscore [ Time Frame: Up to 12 months ]

Central Contacts

Related Studies